Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus single-fraction radiotherapy before surgery in early-stage NSCLC
NL-OMON52295Phase 2Recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Aug 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Vrije University Medical Center. Primary endpoints: Pathologic response and Safety. Started Aug 2021; status: recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON52295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52295.